Civitas Therapeutics

It is no longer a rare sight to see a biotech file for bankruptcy but it still raises the eyebrows when a firm established nearly 30 years ago which had a significant degree of success such as Acorda

Two years ago, Acorda Therapeutics Inc. CEO Ron Cohen was sitting in the witness chair in the US District Court for the District of Delaware, trying to convince US District Judge Leonard Stark that

Two years ago, Acorda Therapeutics Inc. CEO Ron Cohen was sitting in the witness chair in the US District Court for the District of Delaware, trying to convince US District Judge Leonard Stark that

The US FDA turned away two new drug applications (NDAs) submitted under 505(b)(2) in the last week of August – actions that, once again, highlight the fallacy of viewing this regulatory pathway as an